Cyanocobalamin Injection USP 1000 mcg/mL

Manufacturer
Vitruvias Therapeutics | UBI Pharma Inc.
Effective date
2024-12-20
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
9
Source
full-release
Hydrated at
2026-05-31 21:19:59

Label at a glance#

ProductCyanocobalamin
Active ingredientCyanocobalamin
Label structure15 sections

Indications and uses

Cyanocobalamin is indicated for vitamin B12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible ...

Dosage and administration

Avoid using the intravenous route. Use of this product intravenously will result in almost all of the vitamin being lost in the urine. Parenteral vitamin B12 is the recommended treatment and will be required for the remainder of the patient's life. The oral form is not dependable. A dose of 100 mcg daily for 6 or 7 days should be administered by intramuscular or deep subcutaneous injection. If there is clinical im...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx Only

DESCRIPTION

DESCRIPTION SECTION

Cyanocobalamin Injection, USP is a sterile solution of cyanocobalamin for intramuscular or subcutaneous injection. Each mL contains 1000 mcg cyanocobalamin.

Each vial also contains Sodium Chloride, 0.9%. Benzyl Alcohol, 1.5%, is present as a preservative and Water for Injection q.s. Hydrochloric acid and/or sodium hydroxide may have been added during manufacture to adjust the pH (range 4.5-7.0).

Cyanocobalamin appears as dark red crystals or as an amorphous or crystalline red powder. It is very hygroscopic in the anhydrous form, and sparingly soluble in water (1:80). It is stable to autoclaving for short periods at 121°C. The vitamin B12 coenzymes are very unstable in light.

The chemical name is 5,6-dimethyl-benzimidazolyl cyanocobamide; the molecular formula is C63H88CoN14O14P. The cobalt content is 4.34%. The molecular weight is 1355.39.

The structural formula is represented below.

Chemical StructureChemical Structure

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Vitamin B12 is essential to growth, cell reproduction, hematopoiesis, and nucleoprotein and myelin synthesis.

Cyanocobalamin is quantitatively and rapidly absorbed from intramuscular and subcutaneous sites of injection; the plasma level of the compound reaches its peak within 1 hour after intramuscular injection. Absorbed vitamin B12 is transported via specific B12 binding proteins, transcobalamin I and II to the various tissues. The liver is the main organ for vitamin B12 storage.

Within 48 hours after injection of 100 or 1000 mcg of vitamin B12, 50 to 98% of the injected dose may appear in the urine. The major portion is excreted within the first eight hours. Intravenous administration results in even more rapid excretion with little opportunity for liver storage.

Gastrointestinal absorption of vitamin B12 depends on the presence of sufficient intrinsic factor and calcium ions. Intrinsic factor deficiency causes pernicious anemia, which may be associated with subacute combined degeneration of the spinal cord. Prompt parenteral administration of vitamin B12 prevents progression of neurologic damage.

The average diet supplies about 5 to 15 mcg/day of vitamin B12 in a protein-bound form that is available for absorption after normal digestion. Vitamin B12 is not present in foods of plant origin, but is abundant in foods of animal origin. In people with normal absorption, deficiencies have been reported only in strict vegetarians who consume no products of animal origin (including no milk products or eggs).

Vitamin B12 is bound to intrinsic factor during transit through the stomach; separation occurs in the terminal ileum in the presence of calcium, and vitamin B12 enters the mucosal cell for absorption. It is then transported by the transcobalamin binding proteins. A small amount (approximately 1% of the total amount ingested) is absorbed by simple diffusion, but this mechanism is adequate only with very large doses. Oral absorption is considered too undependable to rely on in patients with pernicious anemia or other conditions resulting in malabsorption of vitamin B12.

Cyanocobalamin is the most widely used form of vitamin B12, and has hematopoietic activity apparently identical to that of the antianemia factor in purified liver extract. Hydroxycobalamin is equally as effective as cyanocobalamin, and they share the cobalamin molecular structure.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Cyanocobalamin is indicated for vitamin B12 deficiencies due to malabsorption which may be associated with the following conditions:

  • Addisonian (pernicious) anemia
  • Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy
  • Fish tapeworm infestation
  • Malignancy of pancreas or bowel
  • Folic acid deficiency

It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin.

Requirements of vitamin B12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation.

Cyanocobalamin Injection, USP is also suitable for the vitamin B12 absorption test (Schilling test).

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Sensitivity to cobalt and/or vitamin B12 is a contraindication.

WARNINGS

WARNINGS SECTION

Patients with early Leber's disease (hereditary optic nerve atrophy) who were treated with cyanocobalamin suffered severe and swift optic atrophy.

Hypokalemia and sudden death may occur in severe megaloblastic anemia which is treated intensely.

Anaphylactic shock and death have been reported after parenteral vitamin B12 administration. An intradermal test dose is recommended before Cyanocobalamin Injection, USP is administered to patients suspected of being sensitive to this drug.

This product contains Benzyl Alcohol. Benzyl Alcohol has been reported to be associated with a fatal "Gasping Syndrome" in premature infants.

This product contains aluminum that may be toxic. Aluminum may reach toxic levels with prolonged parenteral administration if kidney function is impaired.

Premature neonates are particularly at risk because their kidneys are immature, and they require large amounts of calcium and phosphate solutions, which contain aluminum.

Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 mcg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity. Tissue loading may occur at even lower rates of administration.

PRECAUTIONS

PRECAUTIONS SECTION

General Precautions

GENERAL PRECAUTIONS SECTION

Vitamin B12 deficiency that is allowed to progress for longer than 3 months may produce permanent degenerative lesions of the spinal cord. Doses of folic acid greater than 0.1 mg per day may result in hematologic remission in patients with vitamin B12 deficiency. Neurologic manifestations will not be prevented with folic acid, and if not treated with vitamin B12, irreversible damage will result.

Doses of cyanocobalamin exceeding 10 mcg daily may produce hematologic response in patients with folate deficiency. Indiscriminate administration may mask the true diagnosis.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Patients with pernicious anemia should be informed that they will require monthly injections of vitamin B12 for the remainder of their lives. Failure to do so will result in return of the anemia and in development of incapacitating and irreversible damage to the nerves of the spinal cord. Also, patients should be warned about the danger of taking folic acid in place of vitamin B12, because the former may prevent anemia but allow progression of subacute combined degeneration.

A vegetarian diet which contains no animal products (including milk products or eggs) does not supply any vitamin B12. Patients following such a diet, should be advised to take oral vitamin B12 regularly. The need for vitamin B12 is increased by pregnancy and lactation. Deficiency has been recognized in infants of vegetarian mothers who were breast fed, even though the mothers had no symptoms of deficiency at the time.

Laboratory Tests

LABORATORY TESTS SECTION

During the initial treatment of patients with pernicious anemia, serum potassium must be observed closely the first 48 hours and potassium replaced if necessary.

Hematocrit, reticulocyte count, vitamin B12, folate and iron levels should be obtained prior to treatment. Hematocrit and reticulocyte counts should be repeated daily from the fifth to seventh days of therapy and then frequently until the hematocrit is normal. If folate levels are low, folic acid should also be administered. If reticulocytes have not increased after treatment or if reticulocyte counts do not continue at least twice normal as long as the hematocrit is less than 35%, diagnosis or treatment should be reevaluated. Repeat determinations of iron and folic acid may reveal a complicating illness that might inhibit the response of the marrow.

Patients with pernicious anemia have about 3 times the incidence of carcinoma of the stomach as the general population, so appropriate tests for this condition should be carried out when indicated.

Drug/Laboratory Test Interactions

DRUG & OR LABORATORY TEST INTERACTIONS SECTION

Persons taking most antibiotics, methotrexate and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays.

Colchicine, para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long term studies in animals to evaluate carcinogenic potential have not been done. There is no evidence from long-term use in patients with pernicious anemia that cyanocobalamin is carcinogenic. Pernicious anemia is associated with an increased incidence of carcinoma of the stomach, but this is believed to be related to the underlying pathology and not to treatment with cyanocobalamin.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects

TERATOGENIC EFFECTS SECTION

Pregnancy Category C

SPL UNCLASSIFIED SECTION

Adequate and well-controlled studies have not been done in pregnant women. However, vitamin B12 is an essential vitamin and requirements are increased during pregnancy. Amounts of vitamin B12 that are recommended by the Food and Nutrition Board, National Academy of Science-National Research Council for pregnant women (4 mcg daily) should be consumed during pregnancy.

Nursing Mothers

NURSING MOTHERS SECTION

Vitamin B12 is known to be excreted in human milk. Amounts of vitamin B12 that are recommended by the Food and Nutrition Board, National Academy of Science-National Research Council for lactating women (4 mcg daily) should be consumed during lactation.

Pediatric Use

PEDIATRIC USE SECTION

Intake in children should be in the amount (0.5 to 3 mcg daily) recommended by the Food and Nutrition Board, National Academy of Science-National Research Council.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Generalized: Anaphylactic shock and death have been reported with administration of parenteral vitamin B12 (see WARNINGS).

Cardiovascular: Pulmonary edema and congestive heart failure early in treatment; peripheral vascular thrombosis.

Hematological: Polycythemia vera

Gastrointestinal: Mild transient diarrhea

Dermatological: Itching; transitory exanthema

Miscellaneous: Feeling of swelling of entire body

To report SUSPECTED ADVERSE REACTIONS, contact Vitruvias Therapeutics at 1-844-451-5944 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

OVERDOSAGE SECTION

No overdosage has been reported with this drug.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Avoid using the intravenous route. Use of this product intravenously will result in almost all of the vitamin being lost in the urine.

Pernicious Anemia

SPL UNCLASSIFIED SECTION

Parenteral vitamin B12 is the recommended treatment and will be required for the remainder of the patient's life. The oral form is not dependable. A dose of 100 mcg daily for 6 or 7 days should be administered by intramuscular or deep subcutaneous injection. If there is clinical improvement and if a reticulocyte response is observed, the same amount may be given on alternate days for seven doses, then every 3 to 4 days for another 2 to 3 weeks. By this time hematologic values should have become normal. This regimen should be followed by 100 mcg monthly for life. Folic acid should be administered concomitantly if needed.

Patients with Normal Intestinal Absorption

SPL UNCLASSIFIED SECTION

Where the oral route is not deemed adequate, initial treatment similar to that for patients with pernicious anemia may be indicated depending on the severity of the deficiency. Chronic treatment should be with an oral B12 preparation. If other vitamin deficiencies are present, they should be treated.

Schilling Test

SPL UNCLASSIFIED SECTION

The flushing dose is 1000 mcg.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

HOW SUPPLIED

HOW SUPPLIED SECTION

Cyanocobalamin Injection, USP 1000 mcg/mL

NDC 69680-112-10 1 mL VialBoxes of 10
NDC 69680-112-25 1 mL VialBoxes of 25
NDC 69680-113-99 10 mL Multiple Dose VialBoxes of 10
NDC 69680-121-30 30 mL Multiple Dose VialBoxes of 1
NDC 69680-121-05 30 mL Multiple Dose VialBoxes of 5
NDC 69680-121-10 30 mL Multiple Dose VialBoxes of 10

STORAGE AND HANDLING SECTION

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

PROTECT FROM LIGHT
Use only if solution is clear and seal intact.

SPL UNCLASSIFIED SECTION

Product of France

Manufactured for:
Vitruvias Therapeutics
Auburn, Alabama 36830

Code No.: I112 0923R5
Revised: 02/2024

To request additional information or if you have questions concerning this drug please phone Vitruvias Therapeutics at 1-844-451-5944.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA 1088.

L487-05

PRINCIPAL DISPLAY PANEL - 1 mL Vial Box Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Cyanocobalamin
Injection, USP
1000 mcg/mL

NDC 69680–112–10
10 x 1 mL VIALS

For Intramuscular or Subcutaneous Use Only
Each mL contains: Cyanocobalamin 1000 mcg, Sodium Chloride 0.9%,
Benzyl Alcohol 1.5%, Water for Injection q.s. pH (range 4.5 - 7.0)
adjusted with Hydrochloric Acid and/or Sodium Hydroxide.
WARNING: PROTECT FROM LIGHT. Store at 20° to 25°C (68° to
77°F); excursions permitted to 15° to 30°C (59° to 86°F) (See USP
Controlled Room Temperature). Directions for Use: See Package Insert.

Rx Only

Product of France

Mfd. for:
Vitruvias Therapeutics
Auburn, AL 36830

Rev. 03/24

PRINCIPAL DISPLAY PANEL - 1 mL Vial Box Label
PRINCIPAL DISPLAY PANEL - 1 mL Vial Box Label

PRINCIPAL DISPLAY PANEL - 10 mL Vial Box

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Cyanocobalamin
Injection, USP
10,000 mcg/10 mL (1,000 mcg/mL)

NDC 69680–113–99
10 x 10 mL
MULTIPLE DOSE VIALS

For Intramuscular or Subcutaneous Use Only
Each mL contains: Cyanocobalamin 1000 mcg, Benzyl Alcohol 1.5%,
Sodium Chloride 0.9%, Water for Injection q.s. pH (range 4.5 - 7.0)
adjusted with Hydrochloric Acid and/or Sodium Hydroxide.
WARNING: PROTECT FROM LIGHT. Store at 20° to 25°C (68° to 77°F);
excursions permitted to 15° to 30°C (59° to 86°F) (See USP Controlled
Room Temperature).
Directions for Use: See Package Insert.
Product of France

Rx Only

Mfd. for:
Vitruvias Therapeutics
Auburn, AL 36830

Rev. 03/24

PRINCIPAL DISPLAY PANEL - 10 mL Vial Box
PRINCIPAL DISPLAY PANEL - 10 mL Vial Box

PRINCIPAL DISPLAY PANEL - 30 mL Vial Box

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Cyanocobalamin
Injection, USP
30,000 mcg/30 mL (1,000 mcg/mL)

NDC 69680–121–05
5 x 30 mL
MULTIPLE DOSE VIALS

For Intramuscular or Subcutaneous Use Only
Each mL contains: Cyanocobalamin 1000 mcg, Benzyl Alcohol 1.5%,
Sodium Chloride 0.9%, Water for Injection q.s. pH (range 4.5 - 7.0)
adjusted with Hydrochloric Acid and/or Sodium Hydroxide.
WARNING: PROTECT FROM LIGHT. Store at 20° to 25°C (68° to 77°F);
excursions permitted to 15° to 30°C (59° to 86°F) (See USP Controlled
Room Temperature).
Directions for Use: See Package Insert.
Product of France

Rx Only

Mfd. for:
Vitruvias Therapeutics
Auburn, AL 36830

Rev. 03/24

PRINCIPAL DISPLAY PANEL - 30 mL Vial Box
PRINCIPAL DISPLAY PANEL - 30 mL Vial Box

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
309594cyanocobalamin 1000 MCG/ML Injectable SolutionPSN9
309594vitamin B12 1 MG/ML Injectable SolutionSCD9
309594cyanocobalamin 1 MG/ML Injectable SolutionSY9
309594cyanocobalamin 1000 MCG/ML Injectable SolutionSY9

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
CYANOCOBALAMIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
b82b4008-22fd-05f5-6cc6-c0a6e81c65b8Product name220240805
362d7abb-94e6-4c60-9a58-266894157713Product name120231023
6bd95106-a412-1dad-b9cc-4cb74bfb27ceProduct name220230315
f1e0dc7e-7d61-4625-b6d9-4894927679d7Product name220211025
e4870509-7e28-6f92-f0be-dd3dd889a9cfProduct name520200810
6e9d4a47-c464-b93e-aebc-ad7bffc9c4cdProduct name220190619
444b3e50-f226-46ef-bfca-2e7035d140cdProduct name120190611
816b97af-edc5-4060-aff1-b814bdbcad50Product name120190415
7cda52fc-125f-421c-8fea-bc1974370c49Product name220180703
d206bb34-ea65-399d-70d9-834f22dc2c18Product name320170724
419aab54-5d5a-4146-9453-026d4a9991beProduct name220170525
d5e51f11-ad28-caa4-4b49-4143974782adProduct name120150831
290f523a-f9db-9774-b5a9-e1f908ac1782Product name120150828
89dac932-b90a-4410-9ab1-84c53e57de25Product name120150316
5668b646-cd56-c3c7-bdea-3f6b1a8840dbProduct name120140508
684ea482-2e8b-14af-5664-b98f1e402036Product name120140508
810ab97e-f109-f41c-7c83-6a652a9cbf43Product name120140508
87711080-88eb-65c5-b2dd-bf99e700a372Product name120140508
8dbefedf-0a0d-a224-5a3c-66dc9e11c2ddProduct name120140508
9869efd7-d6dd-0665-5b67-53adbe6ef15eProduct name120140508
b060cc1a-fe47-856b-0b77-4448b5963de8Product name120140508
c6b65c52-69c7-df49-550a-a50c137f6218Product name120140508
ec2149b3-5c6d-5344-f757-c86411073075Product name120140508
ed912195-5da0-0f2f-6f4b-3ef17710cbe3Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
69680-112-01Cyanocobalamin1 mL in 1 VIALINJECTION, SOLUTION19
69680-112-10Cyanocobalamin10 in 1 BOXINJECTION, SOLUTION109
69680-112-25Cyanocobalamin25 in 1 BOXINJECTION, SOLUTION259
69680-113-10Cyanocobalamin10 mL in 1 VIAL, MULTI-DOSEINJECTION, SOLUTION109
69680-113-99Cyanocobalamin10 in 1 BOXINJECTION, SOLUTION109
69680-121-05Cyanocobalamin5 in 1 BOXINJECTION, SOLUTION59
69680-121-05Cyanocobalamin30 mL in 1 VIAL, MULTI-DOSEINJECTION, SOLUTION309
69680-121-10Cyanocobalamin10 in 1 BOXINJECTION, SOLUTION109
69680-121-10Cyanocobalamin30 mL in 1 VIAL, MULTI-DOSEINJECTION, SOLUTION309
69680-121-30Cyanocobalamin1 in 1 BOXINJECTION, SOLUTION19
69680-121-30Cyanocobalamin30 mL in 1 VIAL, MULTI-DOSEINJECTION, SOLUTION309

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
69680-112CYANOCOBALAMIN INJECTION, SOLUTION [VITRUVIAS THERAPEUTICS]9Current NDC, Legacy NDC, 3 package rows20241222_2117af8a-723f-4e2f-98a6-83ad2c423751.zip
69680-113CYANOCOBALAMIN INJECTION, SOLUTION [VITRUVIAS THERAPEUTICS]9Current NDC, Legacy NDC, 2 package rows20241222_2117af8a-723f-4e2f-98a6-83ad2c423751.zip
69680-121CYANOCOBALAMIN INJECTION, SOLUTION [VITRUVIAS THERAPEUTICS]9Current NDC, Legacy NDC, 6 package rows20241222_2117af8a-723f-4e2f-98a6-83ad2c423751.zip

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
69680-112-01ML - Milliliter69680-11225fb6be9-311f-4326-a323-612604e802f612022-02-07
69680-112-10ML - Milliliter69680-11233ae0f60-8f6c-4144-8e87-e2ae05f541e612019-07-02
69680-112-25ML - Milliliter69680-11278c64154-ebb8-4b3e-8546-a88ee5008ae012019-01-24
69680-113-10ML - Milliliter69680-11367ea1884-e07c-4ba0-a09e-2ce77db24a5112022-10-06
69680-113-99ML - Milliliter69680-1136a3b7887-2c39-4775-bbda-7a3c2efd174912019-01-24
69680-121-05ML - Milliliter69680-1218f3014c5-13a8-4063-a84b-d0f10462782d12020-03-10
69680-121-10ML - Milliliter69680-121e747aa1f-5344-44f6-b7e4-4f3529f74e7f12021-10-08
69680-121-30ML - Milliliter69680-121f5b59a8b-f5d1-4cb5-b265-a78d13a01a1f12020-04-20

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 4 matching rows.

NDC Codes#

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 12 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 43.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A209255-001CYANOCOBALAMINCYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-18

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A209255-001AP

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-09-14 22:38:342026-08A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-1884e616aacf4f…
2026-08-18 06:07:402026-07A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-18caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-18011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-1831067a03dcf5…
2025-08-23 18:47 UTC2025-08A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-186a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-18fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-18b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-1803ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-182680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-185bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-18d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-18d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-1879d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-18301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-181e350fbaab3a…
2024-05-31 18:47 UTC2024-05A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-188072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-185c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-185d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-184b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-1874a2ff9319b5…
2022-03-09 01:35 UTC2022-03A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-18bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-18782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-1887673890dc5c…
2021-03-12 10:30 UTC2021-03A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-185aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-188869cabd3fbd…
2020-11-12 02:37 UTC2020-11A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-18c0c555d07b60…
2019-12-14 00:12 UTC2019-12A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-183f01610625f2…
2019-09-15 20:21 UTC2019-09A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-18b00525d2431f…
2019-07-19 19:46 UTC2019-07A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-18ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-186a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-181c564ffb4f44…
2023-12-20 04:57 UTC2023-12A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-18ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-18a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-189b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-18a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-183f0d92c62455…
2023-05-13 08:27 UTC2023-05A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-18053a50430f4f…
2023-01-26 05:58 UTC2023-01A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-183bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-183a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A209255-001CYANOCOBALAMIN1MG/MLINJECTABLE / INJECTIONAP2018-12-18f41ea6bd6efb…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 43 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-09-14 22:38:342026-08A209255-001AP184e616aacf4f…
2026-08-18 06:07:402026-07A209255-001AP1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A209255-001AP1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A209255-001AP131067a03dcf5…
2025-08-23 18:47 UTC2025-08A209255-001AP16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A209255-001AP1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A209255-001AP1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A209255-001AP103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A209255-001AP12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A209255-001AP15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A209255-001AP1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A209255-001AP1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A209255-001AP179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A209255-001AP1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A209255-001AP11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A209255-001AP18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A209255-001AP15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A209255-001AP15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A209255-001AP14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A209255-001AP174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A209255-001AP1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A209255-001AP1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A209255-001AP187673890dc5c…
2021-03-12 10:30 UTC2021-03A209255-001AP15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A209255-001AP18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A209255-001AP1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A209255-001AP13f01610625f2…
2019-09-15 20:21 UTC2019-09A209255-001AP1b00525d2431f…
2019-07-19 19:46 UTC2019-07A209255-001AP1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A209255-001AP16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A209255-001AP11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A209255-001AP1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A209255-001AP1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A209255-001AP19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A209255-001AP1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A209255-001AP13f0d92c62455…
2023-05-13 08:27 UTC2023-05A209255-001AP1053a50430f4f…
2023-01-26 05:58 UTC2023-01A209255-001AP13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A209255-001AP13a93d1ddd44b…
2022-10-28 04:53 UTC2022-10A209255-001AP1f41ea6bd6efb…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
CyanocobalaminCYANOCOBALAMINVitruvias Therapeutics2117af8a-723f-4e2f-98a6-83ad2c4237512024-12-20Warnings, Adverse reactionsExact identifier
ndc (package): 69680-112-25
ndc (package): 69680-112-01
ndc (package): 69680-113-10
ndc (package): 69680-121-30
ndc (package): 69680-112-10
ndc (package): 69680-113-99
ndc (package): 69680-121-10
ndc (package): 69680-121-05
ndc (product): 69680-112
ndc (product): 69680-113
ndc (product): 69680-121
ndc11 (package): 69680011399
ndc11 (package): 69680011310
ndc11 (package): 69680012130
ndc11 (package): 69680012110
ndc11 (package): 69680011210
ndc11 (package): 69680012105
ndc11 (package): 69680011201
ndc11 (package): 69680011225
spl id: 7c3b0e85-bd17-4998-aaf4-1a873a357ab4
spl set id: 2117af8a-723f-4e2f-98a6-83ad2c423751

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.